Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166088 | 0.86 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL21165813 | 0.82 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL21165975 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL21166014 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL21166199 | 0.74 | EPHX2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22419964 | 0.74 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL19686899 | 0.73 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL12909937 | 0.71 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL12791409 | 0.70 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL11223839 | 0.70 | ATM (0.42) | TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CHRNB2 504/4885CHRNA4 365/4885CHRNB4 542/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CHRNB2 504/4885CHRNA4 365/4885CHRNB4 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.